Table 2.

Clinical and pathological data summaries in both training and testing cohort

		Training group (N = 99)		Testing group (N = 97)		P value
Age (yrs.)		45.9 ± 13.35		46.64 ± 15.90		0.961
< 30		17(17.2%)		14(14.4%)
30–50		35(35.4%)		40(41.2%)
> 50		47(47.5%)		43(44.3%)
Ki-67 expression (%)		32.37 ± 28.01		25.05 ± 26.35		0.946
< 50		59(67.0%)		74(84.1%)
50–75		20(22.7%)		5(5.7%)
> 75		9(10.2%)		9(10.2%)
CA-125 level(IU/L)		553.32 ± 994.28		300.30 ± 452.27		0.000
< 35		15(22.7%)		18(27.7%)
35–200		17(25.8%)		24(36.9%)
200–500		13(19.7%)		10(15.4%)
> 500		21(31.8%)		13(20.0%)
Category						0.980
Borderline tumor		47(47.5%)		44(45.4%)
Malignancies		52(52.5%)		53(54.6%)
Endometroid cancer		2(2.0%)		1(1.0%)
Low-grade adenocarcinoma		0(0.0%)		3(3.1%)
Clear cell type		1(1.%)		4(4.1%)
Serous carcinoma		45(45.5%)		38(39.2%)
Mucinous carcinoma		2(2.0%)		5(5.2%)
Mixed carcinoma		2(2.0%)		2(2.1%)